Report cover image

Yellow Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Global Markets Direct
Published Jul 29, 2022
Length 95 Pages
SKU # GMD17380578

Description

Yellow Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Yellow Fever - Drugs In Development, 2022, provides an overview of the Yellow Fever (Infectious Disease) pipeline landscape.

Yellow fever is an acute systemic illness (hemorrhagic fever) caused by the Flavivirus. It is spread by mosquitoes. Symptoms include irregular heartbeats, bleeding, vomiting, coma, delirium, fever, headache and muscle aches. There is no specific treatment for yellow fever but can be treated to relieve the symptoms.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Yellow Fever - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Yellow Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Yellow Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Yellow Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 4, 9 and 5 respectively. Similarly, the Universities portfolio in Phase I and Discovery stages comprises 1 and 3 molecules, respectively.

Yellow Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Yellow Fever (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Yellow Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Yellow Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Yellow Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Yellow Fever (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Yellow Fever (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Yellow Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

95 Pages
Introduction
Global Markets Direct Report Coverage
Yellow Fever – Overview
Yellow Fever – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Yellow Fever – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Yellow Fever – Companies Involved in Therapeutics Development
Bavarian Nordic A/S
BioCryst Pharmaceuticals Inc
Biological E Ltd
China National Pharmaceutical Group Corp
Collaborations Pharmaceuticals Inc
Curevac NV
Emergex Vaccines Holding Ltd
Ennaid Therapeutics LLC
Fab’entech SA
iBio Inc
Imutex Ltd
Inventprise LLC
Mabloc LLC
Medigen Inc
Najit Technologies Inc
Sanofi
Serum Institute of India Pvt Ltd
SmartBioTech
Theravectys SA
Tychan Pte Ltd
Universal Stabilization Technologies Inc
Yellow Fever – Drug Profiles
AGS-v PLUS – Drug Profile
Drug for Yellow Fever – Drug Profile
EMX-001 – Drug Profile
ETxR-12 – Drug Profile
FDX-000 – Drug Profile
flavivirus vaccine – Drug Profile
galidesivir – Drug Profile
Hydrovax-YFV – Drug Profile
Monoclonal Antibodies for Yellow fever – Drug Profile
SinSaVak – Drug Profile
Small Molecule for Yellow Fever – Drug Profile
Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections – Drug Profile
SP-0218 – Drug Profile
Synthetic Peptides for Yellow Fever – Drug Profile
TY-014 – Drug Profile
yellow fever vaccine – Drug Profile
yellow fever vaccine – Drug Profile
yellow fever vaccine – Drug Profile
yellow fever vaccine – Drug Profile
yellow fever vaccine – Drug Profile
yellow fever vaccine – Drug Profile
yellow fever vaccine – Drug Profile
yellow fever vaccine – Drug Profile
yellow fever vaccine – Drug Profile
yellow fever vaccine – Drug Profile
yellow fever vaccine – Drug Profile
yellow fever vaccine – Drug Profile
Yellow Fever – Dormant Projects
Yellow Fever – Product Development Milestones
Featured News & Press Releases
Apr 07, 2022: Emergex signs agreement with ATCC to advance studies of its yellow fever booster vaccine candidate
Aug 19, 2020: Emergex and Bio-Manguinhos/Fiocruz elucidate T cell epitopes produced by commercial yellow fever vaccine
Jul 30, 2020: SMART Researchers develop potential antibody treatment for yellow fever in seven months
Jul 29, 2020: NEJM study demonstrates safety and efficacy of first novel monoclonal antibody specifically developed to treat yellow fever
Nov 18, 2019: WuXi Biologics congratulates Tychan on the world's first yellow fever antibody tested safe and efficacious in human volunteers
May 09, 2019: BioCryst completes Phase 1 clinical trial of galidesivir
Jan 02, 2019: BioCryst initiates phase 1 clinical trial of Galidesivir
Dec 13, 2018: WuXi Biologics congratulates Tychan on first-in-class monoclonal antibody for Yellow fever after record 7 months of development
Dec 06, 2018: Tychan Begins Phase I Trials for First Ever Yellow Fever Drug
Sep 17, 2018: BioCryst receives additional $3.5 million to fund clinical trials of Galidesivir in Yellow Fever
Jul 27, 2016: Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever Vaccine
Jul 27, 2016: NIH launches early-stage yellow fever vaccine trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Yellow Fever, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Universities/Institutes, 2022
Table 4: Products under Development by Companies, 2022
Table 5: Products under Development by Universities/Institutes, 2022
Table 6: Number of Products by Stage and Target, 2022
Table 7: Number of Products by Stage and Mechanism of Action, 2022
Table 8: Number of Products by Stage and Route of Administration, 2022
Table 9: Number of Products by Stage and Molecule Type, 2022
Table 10: Yellow Fever – Pipeline by Bavarian Nordic A/S, 2022
Table 11: Yellow Fever – Pipeline by BioCryst Pharmaceuticals Inc, 2022
Table 12: Yellow Fever – Pipeline by Biological E Ltd, 2022
Table 13: Yellow Fever – Pipeline by China National Pharmaceutical Group Corp, 2022
Table 14: Yellow Fever – Pipeline by Collaborations Pharmaceuticals Inc, 2022
Table 15: Yellow Fever – Pipeline by Curevac NV, 2022
Table 16: Yellow Fever – Pipeline by Emergex Vaccines Holding Ltd, 2022
Table 17: Yellow Fever – Pipeline by Ennaid Therapeutics LLC, 2022
Table 18: Yellow Fever – Pipeline by Fab’entech SA, 2022
Table 19: Yellow Fever – Pipeline by iBio Inc, 2022
Table 20: Yellow Fever – Pipeline by Imutex Ltd, 2022
Table 21: Yellow Fever – Pipeline by Inventprise LLC, 2022
Table 22: Yellow Fever – Pipeline by Mabloc LLC, 2022
Table 23: Yellow Fever – Pipeline by Medigen Inc, 2022
Table 24: Yellow Fever – Pipeline by Najit Technologies Inc, 2022
Table 25: Yellow Fever – Pipeline by Sanofi, 2022
Table 26: Yellow Fever – Pipeline by Serum Institute of India Pvt Ltd, 2022
Table 27: Yellow Fever – Pipeline by SmartBioTech, 2022
Table 28: Yellow Fever – Pipeline by Theravectys SA, 2022
Table 29: Yellow Fever – Pipeline by Tychan Pte Ltd, 2022
Table 30: Yellow Fever – Pipeline by Universal Stabilization Technologies Inc, 2022
Table 31: Yellow Fever – Dormant Projects, 2022
Table 32: Yellow Fever – Dormant Projects, 2022 (Contd..1)
List of Figures
Figure 1: Number of Products under Development for Yellow Fever, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products under Development by Universities/Institutes, 2022
Figure 4: Number of Products by Targets, 2022
Figure 5: Number of Products by Stage and Targets, 2022
Figure 6: Number of Products by Mechanism of Actions, 2022
Figure 7: Number of Products by Stage and Mechanism of Actions, 2022
Figure 8: Number of Products by Routes of Administration, 2022
Figure 9: Number of Products by Stage and Routes of Administration, 2022
Figure 10: Number of Products by Molecule Types, 2022
Figure 11: Number of Products by Stage and Molecule Types, 2022

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us